Citations

Clear

3485 citation(s) found for "Sy, Sarah".

Comprehensive morphologic characterization of bone marrow biopsy findings in a large cohort of patients with VEXAS syndrome: A single-institution longitudinal study of 111 bone marrow samples from 52 patients
Olteanu, Horatiu , Patnaik, Mrinal M. , Chen, Dong , He, Rong , Viswanatha, David S., Mangaonkar, Abhishek A. , Kourelis, Taxiarchis , Hines, Alexander , Reichard, Kaaren K. , Herrick, Jennifer L. , Chen, Dong , He, Rong , Viswanatha, David, Hines, Alexander S , Gibson, Sarah E , Koster, Matthew J. , Warrington, Kenneth J. , Go, Ronald S. , Gibson, Sarah E. , Peterson, Jess F.

Mayo Clinic

American Journal of Clinical Pathology | December 22, 2023 | Volume: 161 | Issue: 6 | Pages: 609-624

10.1093/ajcp/aqad186 | PMID 38413044 Get It

Abstract Objectives VEXAS syndrome is an adult-onset autoinflammatory disease caused by a somatic pathogenic mutation in the UBA1 (ubiquitin-like modifier activating enzyme 1) gene. Patients present with rheumatologic manifestations and cytopenias and may have an increased predisposition to myelodysplastic syndrome (MDS) and plasma cell neoplasms. Prior studies have reported on the peripheral blood and bone marrow findings in patients with VEXAS syndrome. Due to the protean clinical presentation and lack of specificity of morphologic features (eg, vacuoles in early erythroid and granulocytic precursors), an optimal screening methodology to identify these patients in a timely fashion is desirable. Methods To further evaluate and describe the salient diagnostic morphologic features in VEXAS syndrome, we carried out a comprehensive study of the largest single-institution cohort to date. Diagnostic and follow-up bone marrow biopsy specimens from 52 male patients with molecularly identified VEXAS syndrome underwent central review. Results Cytopenias were common in all cases, primarily macrocytic anemia, monocytopenia, and thrombocytopenia. Bone marrow aspirate and biopsy were often hypercellular, with an increased myeloid/erythroid ratio, granulocytic hyperplasia with left shift, erythroid left shift, and megakaryocyte hyperplasia, which exhibited a range of striking morphologic findings. Distinctly vacuolated myeloid and erythroid precursors were seen in more than 95% of cases. Conclusions Our data reveal potential novel diagnostic features, such as a high incidence of monocytopenia and distinct patterns of atypical megakaryopoiesis, that appear different from dysmegakaryopoiesis typically associated with MDS. In our experience, those findings are suggestive of VEXAS, in the appropriate clinical context.
Single‐use versus reusable rhinolaryngoscopes for inpatient otorhinolaryngology consults: Resident and patient experience
Bowen, Andrew J. , Macielak, Robert J. , Fussell, Wanda L., Yeakel, Sarah, McMillan, Ryan A. , Goates, Andrew J. , Awadallah, Andrew S. , Ekbom, Dale C. , Bowen, Andrew Jay , Macielak, Robert James , Fussell, Wanda, McMillan, Ryan, Goates, Andrew, Awadallah, Andrew

Mayo Clinic

Laryngoscope Investigative Otolaryngology | December 19, 2023 | Volume: 9 | Issue: 1 | Pages: No page available

10.1002/lio2.1203 | PMID 38362188 Get It

AbstractObjectivesSingle‐use rhinolaryngoscopes were brought to market in 2019 as an alternative to traditional reusable scopes and have garnered interest across settings given portability and potential cost advantages. While single‐use was previously evaluated compared to traditional devices, the overall impact to the consult experience for both users and patients has not been captured.MethodsEighteen residents performed consults with both single‐use and reusable rhinolaryngoscope systems on alternating weeks. A five‐question cumulative survey administered across three assessment points over a 12‐week period using a five‐point rating system to rate favorability. Residents and patients also completed four‐point scale surveys following procedure(s) to capture the consult experience. Statistical analyses were performed to measure significance differences between survey responses between the two systems.ResultsSingle‐use rhinolaryngoscopes received higher overall ratings compared with reusables across each metric captured including overall consult time (4.3 vs. 2.2, p < .001), multiscope consults (4.4 vs. 3.1, p < .001), patient communication (4.6 vs. 2.1, p < .001), teaching opportunities (4.6 vs. 2.1, p < .001), and overall ease of use (4.7 vs. 2.6, p < .001). Residents rated single‐use higher than reusable after each procedure in terms of ease of use (1.07 vs. 2.68, p < .001) and visual clarity (1.27 vs. 1.89, p = .003), while patients rated single‐use higher for understanding of illness (3.9 vs. 3.1, p < .001) and understanding of treatment rationale (3.9 vs. 3.1, p < .001).ConclusionResident and patient experience feedback favored single‐use rhinolaryngoscopes compared to reusable scope technology across multiple surveyed measurables. Single‐use rhinolaryngoscopes provide a viable tool for otorhinolaryngologist and other clinicians to perform rhinolaryngoscopy consults.Level of Evidence4.
Abstract 13633: Modern Treatment Patterns in Incident Pulmonary Arterial Hypertension (PAH) Patients: Real-World Data From the Pulmonary Hypertension Association (PHA) Registry
Kime, Noah , Williams, Kayleen , Rendon, Gabriela Gomez , Mathai, Stephen C. , Mathai, Stephen C , Paoli, Carly J. , Tonelli, Adriano R. , Cajigas, Héctor , Khan, Sarah L. , Sahay, Sandeep

Mayo Clinic

Circulation | December 19, 2023 | Volume: 148 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.148.suppl_1.13633 Get It

Purpose: New 2022 European Society of Cardiology/European Respiratory Society PAH guidelines recommend treatment guided by a multi-parameter risk assessment. 1 Patients with low/intermediate risk without cardiopulmonary comorbidities should start dual PAH combination therapy; those with cardiopulmonary comorbidities should be reassessed early for rapid escalation to dual therapy. Initial triple therapy is recommended for high-risk patients. We examined use of dual and triple PAH therapy in the US (before guideline update). Methods: We used the Pulmonary Hypertension Association Registry (PHAR), a prospective US registry of pulmonary hypertension (PH) patients, enrolled within 6 months of their first outpatient visit at one of 54 participating PH care centers in the US, between Sep 2015-Jun 2022. We included adults (≥18 years at enrollment) with incident PAH (newly diagnosed and treated within 6 months of enrollment) and ≥1 follow-up clinic visit post baseline visit. Chronic thromboembolic PH patients were excluded. Results: We analyzed (descriptive statistics) 794 incident patients (baseline characteristics in Table 1). Treatment patterns at baseline (n=794)/last follow-up visit (n=610) were 289 (36.4%)/102 (16.7%) on monotherapy, 419 (52.8%)/314 (51.5%) on dual combination, 83 (10.5%)/179 (29.3%) on triple combination therapy, respectively. Mean time from enrollment to dual and triple combination therapy was 86.1 (standard deviation [SD]: 209.0) and 346.1 days (SD: 430.8), respectively. Conclusions: Among incident PHAR patients, half received initial dual and 10% triple upfront combination therapy. At last follow-up, most (>80%) patients had escalated to dual/triple combination therapies. Clinical Implications: At PH care centers, most incident PHAR patients are escalated to dual and triple therapy (at last follow-up) per current guidelines. Reference 1. Humbert M, et al. Eur Heart J. 2022;43:3618-731.
Clinicopathologic Findings in Patients With Paraneoplastic Neuropathies and Antibodies Strongly Associated With Cancer
Granger, Andre , Rajnauth, Tina , Lahoria, Rajat , Dubey, Divyanshu , Mills, John R. , Mauermann, Michelle L. , Berini, Sarah E. , Spinner, Robert J. , Dyck, P. James B. , Strong, Michael J. , Mills, J R , Strong, Michael J , Dubey, Divyanshu , Mauermann, Michelle L , Klein, Christopher J.

Mayo Clinic

Neurology | December 18, 2023 | Volume: 102 | Issue: 2 | Pages: No page available

10.1212/wnl.0000000000207982 | PMID 38165318 Get It

Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery
Albain, Kathy S. , Yau, Christina , Petricoin, Emanuel F. , Wolf, Denise M. , Lang, Julie E. , Chien, A. Jo , Haddad, Tufia C. , Forero-Torres, Andres , Wallace, Anne M. , Kaplan, Henry G. , Euhus, David , Nanda, Rita , Clark, Amy S. , Godellas, Constantine , Tripathy, Debu , Lu, Janice , Yung, Rachel L. , Wulfkuhle, Julia , Krings, Gregor , Chen, Yunn‐Yi , Potter, David A. , Stringer-Reasor, Erica , Blair, Sarah L. , Asare, Smita , Wilson, Amy , Hirst, Gillian L. , Singhrao, Ruby , Buxton, Meredith , Clennell, Julia L. , Sanil, Ashish, Matthews, Jeffrey B. , Melisko, Michelle , Perlmutter, Jane , Symmans, W. Fraser , Veer, Laura J. van’t , Yee, Douglas , Berry, Donald A. , Haddad, Tufia C , Kaplan, Henry , Pusztai, Lajos , Euhus, David , Nanda, Rita , Elias, Anthony D , Clark, Amy S , Godellas, Constantine , Boughey, JC , Isaacs, Claudine , Tripathy, Debasish , Lu, Janice , Yung, Rachel L , Gallagher, Rosa I , Wulfkuhle, Julia D , Brown-Swigart, Lamorna , Krings, Gregor , Chen, Yunn Yi , Potter, David A , Stringer-Reasor, Erica , Blair, Sarah L , Asare, Smita M , Wilson, Amy , Hirst, Gillian L , Singhrao, Ruby , Buxton, Meredith , Clennell, Julia L , Berry, Scott , Asare, Adam L , Matthews, Jeffrey B , DeMichele, Angela , Hylton, Nola M. , Melisko, Michelle , Perlmutter, Jane , Rugo, Hope S , Symmans, W Fraser , Yee, Douglas , Berry, Donald , Esserman, Laura J , Pusztai, Lajos , Elias, Anthony , Boughey, Judy C. , Isaacs, Claudine , Gallagher, Rosa I. , Swigart, Lamorna Brown , Asare, Adam L. , DeMichele, Angela , Rugo, Hope S. , Esserman, Laura J.

Mayo Clinic

Clinical Cancer Research | December 18, 2023 | Volume: 30 | Issue: 4 | Pages: 729-740

10.1158/1078-0432.ccr-22-2256 | PMID 38109213 Get It

Abstract Purpose: The neutralizing peptibody trebananib prevents angiopoietin-1 and angiopoietin-2 from binding with Tie2 receptors, inhibiting angiogenesis and proliferation. Trebananib was combined with paclitaxel±trastuzumab in the I-SPY2 breast cancer trial. Patients and Methods: I-SPY2, a phase II neoadjuvant trial, adaptively randomizes patients with high-risk, early-stage breast cancer to one of several experimental therapies or control based on receptor subtypes as defined by hormone receptor (HR) and HER2 status and MammaPrint risk (MP1, MP2). The primary endpoint is pathologic complete response (pCR). A therapy “graduates” if/when it achieves 85% Bayesian probability of success in a phase III trial within a given subtype. Patients received weekly paclitaxel (plus trastuzumab if HER2-positive) without (control) or with weekly intravenous trebananib, followed by doxorubicin/cyclophosphamide and surgery. Pathway-specific biomarkers were assessed for response prediction. Results: There were 134 participants randomized to trebananib and 133 to control. Although trebananib did not graduate in any signature [phase III probabilities: Hazard ratio (HR)-negative (78%), HR-negative/HER2-positive (74%), HR-negative/HER2-negative (77%), and MP2 (79%)], it demonstrated high probability of superior pCR rates over control (92%–99%) among these subtypes. Trebananib improved 3-year event-free survival (HR 0.67), with no significant increase in adverse events. Activation levels of the Tie2 receptor and downstream signaling partners predicted trebananib response in HER2-positive disease; high expression of a CD8 T-cell gene signature predicted response in HR-negative/HER2-negative disease. Conclusions: The angiopoietin (Ang)/Tie2 axis inhibitor trebananib combined with standard neoadjuvant therapy increased estimated pCR rates across HR-negative and MP2 subtypes, with probabilities of superiority &gt;90%. Further study of Ang/Tie2 receptor axis inhibitors in validated, biomarker-predicted sensitive subtypes is warranted.
498: VENTILATOR-ASSOCIATED PNEUMONIA DEVELOPMENT BASED ON CHLORHEXIDINE EXPOSURE AFTER NEW TRACHEOSTOMY
Thompson, Hailey, Vollmer, Nicholas , Kooda, Kirstin , Shah, Aditya , Chalmers, Sarah , Nei, Andrea M. , Mara, Kristin C.

Mayo Clinic

Critical Care Medicine | December 14, 2023 | Volume: 52 | Issue: 1 | Pages: S223-S223

10.1097/01.ccm.0001000172.80066.20 Get It

1372: INDIVIDUALIZED PREDICTION OF CRITICAL ILLNESS IN OLDER ADULTS
Minteer, Sarah, Boswell, Christopher L. , García-Méndez, Juan , Gajic, Ognjen, Herasevich, Svetlana , Dong, Yue , Garcia-Mendez, Juan, Barwise, Amelia

Mayo Clinic

Critical Care Medicine | December 14, 2023 | Volume: 52 | Issue: 1 | Pages: S657-S657

10.1097/01.ccm.0001003648.88943.e8 Get It

1224: THINK POSITIVE: IMPROVING INTERDISCIPLINARY INTRAVENOUS MEDICATION TITRATION MANAGEMENT
Thomas, Tracy A., Sederstrom, Jane, Munch, Paula, Petti, Jamie, Kiley, Brigid, Saint-Amour, Shae, Nyquist, Sharon, Thomas, Tracy, Davis, Kimberly, Black, Sarah

Mayo Clinic

Critical Care Medicine | December 14, 2023 | Volume: 52 | Issue: 1 | Pages: S584-S584

10.1097/01.ccm.0001003060.59455.b2 Get It

1220: DESIGN AND IMPLEMENTATION OF A CHECKLIST TO PREVENT CRITICAL ILLNESS IN OLDER PRIMARY CARE PATIENTS
García-Méndez, Juan , Gajic, Ognjen, Minteer, Sarah, Boswell, Christopher L. , Dong, Yue , Herasevich, Svetlana , Minteer, Sarah, Barwise, Amelia

Mayo Clinic

Critical Care Medicine | December 14, 2023 | Volume: 52 | Issue: 1 | Pages: S582-S582

10.1097/01.ccm.0001003044.17828.96 Get It

242: RISK OF ARRHYTHMIA WITH EPINEPHRINE VERSUS NOREPINEPHRINE AFTER OUT-OF-HOSPITAL CARDIAC ARREST
Normand, Sarah , Matthews, Courtney , Brown, Caitlin S. , Mattson, Alicia E , Wieruszewski, Erin D. , Matthews, Courtney, Mara, Kristin C. , Bellolio, Fernanda

Mayo Clinic

Critical Care Medicine | December 14, 2023 | Volume: 52 | Issue: 1 | Pages: S96-S96

10.1097/01.ccm.0000999156.49817.f4 Get It